TET2 and neoplasm: Deletion of TET2 in colon tumor cells reduces chemokine and PD‐L1 expression, as well as tumor lymphocyte infiltration, allowing tumors to evade antitumor immunity and resist anti‐PD‐L1 therapy [254].